Michael Landsittel Sells 10,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares of the company’s stock, valued at approximately $4,965,030. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Landsittel also recently made the following trade(s):

• On Thursday, March 28th, Michael Landsittel sold 5,000 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.00, for a total transaction of $475,000.00.
• On Friday, March 15th, Michael Landsittel sold 13,734 shares of Blueprint Medicines stock. The stock was sold at an average price of $87.78, for a total transaction of $1,205,570.52.
• On Thursday, March 7th, Michael Landsittel sold 5,003 shares of Blueprint Medicines stock. The stock was sold at an average price of $90.69, for a total transaction of $453,722.07.

Blueprint Medicines Stock Up 2.2 %

Shares of NASDAQ BPMC opened at $108.55 on Wednesday. The company has a 50 day simple moving average of $92.17 and a 200-day simple moving average of $81.81. The company has a market capitalization of $6.64 billion, a P/E ratio of -22.57 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. During the same quarter last year, the firm earned ($2.65) EPS. The firm’s revenue for the quarter was up 85.5% on a year-over-year basis. On average, equities research analysts predict that Blueprint Medicines Co. will post -5.38 earnings per share for the current year.

Institutional Trading of Blueprint Medicines

Institutional investors have recently added to or reduced their stakes in the stock. Readystate Asset Management LP acquired a new stake in Blueprint Medicines in the 4th quarter valued at approximately $3,692,000. American Century Companies Inc. increased its holdings in Blueprint Medicines by 5.2% in the 3rd quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock valued at $33,696,000 after purchasing an additional 33,243 shares during the last quarter. Diversified Trust Co increased its holdings in Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after purchasing an additional 318 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Blueprint Medicines by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 757 shares during the last quarter. Finally, Rafferty Asset Management LLC increased its holdings in Blueprint Medicines by 17.4% in the 3rd quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock valued at $8,371,000 after purchasing an additional 24,693 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently weighed in on BPMC shares. Stifel Nicolaus upped their price target on shares of Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Wedbush reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Blueprint Medicines in a research note on Friday, April 26th. JMP Securities increased their price objective on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday. Finally, Citigroup increased their price objective on shares of Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines has a consensus rating of “Hold” and an average target price of $100.31.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.